)
Max India surged 9% to Rs 494, extending its Friday’s 8% rally on BSE, ahead of the board meeting today to review and approve the corporate restructuring plan for the company.
The stock opened at Rs 464 and hit a 52-week high of Rs 505 on BSE. The counter has seen huge trading volumes with a combined around 2 million shares changing hands in first 10 minutes of trade as compared to sub 1 million shares that were traded daily in past two weeks on BSE and NSE.
The meetings of the Investment & Finance Committee (I&FC) and the board of directors of the company will be held on January 27, 2015 to review and approve the corporate restructuring plan for the company, Max India said in a BSE filing.
On January 14, 2015, the company said "Management of the company is in the process of finalising a few options for corporate restructuring, which will be presented to I&FC for its consideration."
The company is in the process of ascertaining the availability of directors to convene a meeting of the I&FC, it said.
Max India Ltd, a diversified firm engaged in the business of life and health insurance, clinical research, healthcare services and manufacturing specialty film.
The stock opened at Rs 464 and hit a 52-week high of Rs 505 on BSE. The counter has seen huge trading volumes with a combined around 2 million shares changing hands in first 10 minutes of trade as compared to sub 1 million shares that were traded daily in past two weeks on BSE and NSE.
The meetings of the Investment & Finance Committee (I&FC) and the board of directors of the company will be held on January 27, 2015 to review and approve the corporate restructuring plan for the company, Max India said in a BSE filing.
On January 14, 2015, the company said "Management of the company is in the process of finalising a few options for corporate restructuring, which will be presented to I&FC for its consideration."
The company is in the process of ascertaining the availability of directors to convene a meeting of the I&FC, it said.
Max India Ltd, a diversified firm engaged in the business of life and health insurance, clinical research, healthcare services and manufacturing specialty film.
